SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: r. peter Dale who wrote (153)2/15/1998 3:50:00 PM
From: Henry Niman  Read Replies (1) of 579
 
It would not be the first time that LGND was the first to initiate a study in a new area. Not sure about ongoing trials, but LGND is definitely going in the direction clinical trails targeting Alzhieher's Disease with SERMs (Vilar headed AHP's Premarin program before becoming LGND CSO). Speaking of being first, as noted in the "Beyond Tamoxifen" paper (see Biotech Boom table of home.att.net for details), the authors did note that LGND is the only company with rexinoids in the clinic.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News